These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12885889)

  • 21. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
    Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
    Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunogenicity study of HPV 6b virus-like particles].
    Liu Y; Liu X; Frazer IH
    Zhonghua Yi Xue Za Zhi; 2002 May; 82(9):587-9. PubMed ID: 12133476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
    Thönes N; Müller M
    Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Papillomavirus-like particles for serology and vaccine development.
    Kirnbauer R
    Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice.
    Mason HS; Ball JM; Shi JJ; Jiang X; Estes MK; Arntzen CJ
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5335-40. PubMed ID: 8643575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.
    Rose RC; Reichman RC; Bonnez W
    J Gen Virol; 1994 Aug; 75 ( Pt 8)():2075-9. PubMed ID: 8046412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
    Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
    Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein.
    Zhang X; Buehner NA; Hutson AM; Estes MK; Mason HS
    Plant Biotechnol J; 2006 Jul; 4(4):419-32. PubMed ID: 17177807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
    PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.
    Liu XS; Abdul-Jabbar I; Qi YM; Frazer IH; Zhou J
    Virology; 1998 Dec; 252(1):39-45. PubMed ID: 9875315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer.
    Brown DR; Bryan JT; Schroeder JM; Robinson TS; Fife KH; Wheeler CM; Barr E; Smith PR; Chiacchierini L; DiCello A; Jansen KU
    J Infect Dis; 2001 Nov; 184(9):1183-6. PubMed ID: 11598842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles.
    Xu YF; Wang QY; Zhang HT; Han YH; Song GX; Xu XM
    Chin Med J (Engl); 2007 Mar; 120(6):503-8. PubMed ID: 17439745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi.
    Varsani A; Williamson AL; Rose RC; Jaffer M; Rybicki EP
    Arch Virol; 2003 Sep; 148(9):1771-86. PubMed ID: 14505089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
    Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
    J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain.
    Ludmerer SW; McClements WL; Wang XM; Ling JC; Jansen KU; Christensen ND
    Virology; 2000 Jan; 266(2):237-45. PubMed ID: 10639310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells.
    Mossadegh N; Gissmann L; Müller M; Zentgraf H; Alonso A; Tomakidi P
    Virology; 2004 Aug; 326(1):57-66. PubMed ID: 15262495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
    Giannini SL; Hanon E; Moris P; Van Mechelen M; Morel S; Dessy F; Fourneau MA; Colau B; Suzich J; Losonksy G; Martin MT; Dubin G; Wettendorff MA
    Vaccine; 2006 Aug; 24(33-34):5937-49. PubMed ID: 16828940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
    Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
    Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses.
    Huang Z; Elkin G; Maloney BJ; Beuhner N; Arntzen CJ; Thanavala Y; Mason HS
    Vaccine; 2005 Mar; 23(15):1851-8. PubMed ID: 15734055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential of a BPV1 L1 VLP vaccine to prevent BPV1- or BPV2-induced pseudo-sarcoid formation and safety and immunogenicity of EcPV2 L1 VLPs in horse.
    Hainisch EK; Abel-Reichwald H; Shafti-Keramat S; Pratscher B; Corteggio A; Borzacchiello G; Wetzig M; Jindra C; Tichy A; Kirnbauer R; Brandt S
    J Gen Virol; 2017 Feb; 98(2):230-241. PubMed ID: 28284277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.